|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/20 Evolutionary Genomics, Inc. 10-K 12/31/19 61:4.4M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 545K
2: EX-3.4 Certificate of Designation HTML 60K
3: EX-10.13 Notice of Termination HTML 15K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 18K
57: R1 Document and Entity Information HTML 56K
39: R2 Consolidated Balance Sheets HTML 97K
20: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
49: R4 Consolidated Statements of Operations HTML 65K
56: R5 Consolidated Statement of Stockholders' Equity HTML 58K
38: R6 Consolidated Statements of Cash Flows HTML 68K
19: R7 Business Activity HTML 24K
48: R8 Summary of Significant Accounting Policies HTML 33K
58: R9 New Accounting Standards HTML 23K
46: R10 Fair Value Measurements HTML 40K
55: R11 Property and Equipment HTML 29K
34: R12 Intangible Assets HTML 29K
15: R13 Income Taxes HTML 67K
45: R14 Stockholders' Equity and Warrants HTML 42K
54: R15 Stock-Based Compensation HTML 53K
33: R16 Commitments and Contingencies HTML 25K
14: R17 Related Parties and Transactions HTML 20K
47: R18 Concentrations HTML 20K
52: R19 Liquidity and Going Concern HTML 21K
32: R20 Summary of Significant Accounting Policies HTML 74K
(Policies)
26: R21 Fair Value Measurements (Tables) HTML 36K
42: R22 Property and Equipment (Tables) HTML 29K
61: R23 Intangible Assets (Tables) HTML 27K
31: R24 Income Taxes (Tables) HTML 68K
25: R25 Stockholders' Equity and Warrants (Tables) HTML 38K
41: R26 Stock-Based Compensation (Tables) HTML 51K
60: R27 Business Activity (Details) HTML 19K
30: R28 Summary of Significant Accounting Policies (Other) HTML 20K
(Details)
27: R29 Summary of Significant Accounting Policies HTML 23K
(Property and Equipment) (Details)
17: R30 Summary of Significant Accounting Policies HTML 25K
(Intangilbe Assets) (Details)
35: R31 Summary of Significant Accounting Policies (Net HTML 33K
Loss Per Common Share) (Details)
50: R32 Fair Value Measurements (Details) HTML 30K
43: R33 Property and Equipment (Details) HTML 37K
18: R34 Intangible Assets (Details) HTML 49K
36: R35 Income Taxes (Narrative) (Details) HTML 31K
51: R36 Income Taxes (Schedule of Income Tax Expense) HTML 42K
(Details)
44: R37 Income Taxes (Income Tax Reconciliation) (Details) HTML 55K
16: R38 Income Taxes (Schedule of Deferred Tax Assets and HTML 49K
Liabilities) (Details)
37: R39 Stockholders' Equity and Warrants (Narrative) HTML 43K
(Details)
23: R40 Stockholders' Equity and Warrants (Summary of HTML 36K
Warrants Activity) (Details)
28: R41 Stock-Based Compensation (Narrative) (Details) HTML 34K
59: R42 Stock-Based Compensation (Summary of Stock Options HTML 62K
Activity) (Details)
40: R43 Commitments and Contingencies (Details) HTML 25K
24: R44 Related Parties and Transactions (Details) HTML 22K
29: R45 Liquidity and Going Concern (Details) HTML 30K
21: XML IDEA XML File -- Filing Summary XML 103K
53: EXCEL IDEA Workbook of Financial Reports XLSX 48K
8: EX-101.INS XBRL Instance -- fnam-20191231 XML 791K
10: EX-101.CAL XBRL Calculations -- fnam-20191231_cal XML 145K
11: EX-101.DEF XBRL Definitions -- fnam-20191231_def XML 228K
12: EX-101.LAB XBRL Labels -- fnam-20191231_lab XML 636K
13: EX-101.PRE XBRL Presentations -- fnam-20191231_pre XML 459K
9: EX-101.SCH XBRL Schema -- fnam-20191231 XSD 94K
22: ZIP XBRL Zipped Folder -- 0001553350-20-000255-xbrl Zip 75K
| Certification |
EXHIBIT 31.1
CERTIFICATION
I, Steve Warnecke, certify that:
1. I have reviewed this annual report on Form 10-K of Evolutionary Genomics, Inc.
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting .
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
| |
|
|
BY: | /s/ Steve Warnecke |
| |
| Chief Executive Officer |
| (principal executive officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/20 | |||
| For Period end: | 12/31/19 | 10-K/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/09/23 Evolutionary Genomics, Inc. 10-K 12/31/22 58:3.3M Edgar Filing LLC/FA 3/22/22 Evolutionary Genomics, Inc. 10-K 12/31/21 56:3.2M Edgar Filing LLC/FA 3/31/21 Evolutionary Genomics, Inc. 10-K 12/31/20 61:3.3M Edgar Filing LLC/FA |